As the obesity epidemic in America worsened throughout the years, many biotechs cropped up hoping to develop weight-loss drugs that would help stem this tide. But now, Novo Nordisk’s diabetes cash cow semaglutide is showing such startlingly effective results in obesity that it may have a head start in cornering the market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,